Industry Trends

Unleashed demand over the past year characterizes the M&A picture in pharma.

With the Inflation Reduction Act now in flux, how will the government and industry respond?

How alternative direct-to-consumer models are changing the landscape for patient access.

The swell of AI-powered digital platforms puts future decision-making under the spotlight.

Why investing in people and training can help drugmakers deal with six pressing challenges in particular in the year ahead.

The importance of expanding your pharma sales forecasting horizon beyond the US. Learn how to effectively navigate country-specific regulatory red flags.

Identifying the inflators and deflators, and the role all stakeholders play.

Decisions and strategies related to remote work, AI, and DE&I are especially evolving.

The CEO discusses the current state of compounding pharmacies and how it built to this point.

Growth is expected due to increased instances of chronic diseases such as cancer and Alzheimer disease.

The Astellas chief commercial officer discusses the impact that the increase in global and local connectivity has had on commercialization, among other trends.

Webinar Date/Time: Wed, Oct 16, 2024 2:00 PM EDT

Webinar Date/Time: Wednesday, October 9th, 2024 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST

The diversification of site-of-care delivery models is accelerating rapidly, creating new go-to-market implications for drug manufacturers—but also new opportunities to drive more fundamental innovation in engagement and access strategies.

Amid shifting operating dynamics in recent years, demands for external expertise have fluctuated—leaving those arrangements that mix innovation and agility likely to win out in pharma decision-making.

A recent study by Morningstar predicts that 16 new weight-loss drugs could be on the market by 2029.

A Harvard Business School Healthcare Alumni Association Q&A with Jeremy Goldberg of Arsenal Capital Partners.

Webinar Date/Time: Thursday, October 3, 2024 at 2pm EDT|11am PDT|7pm BST|8pm CEST

Pharm Exec’s latest sampling of notable biopharma brand approvals and launches all have unique stories to tell—from the winding journeys to innovative “firsts” to new momentum for milestones to come.

Surviving a long road, novel next-generation treatment offers hope for major depressive disorder.

Key approval signals progress in addressing immune-mediated inflammatory diseases.

A breakthrough for biomarker-altered breast cancer—but broader challenges remain.

New cardiovascular indication builds on treatment’s fast-growing legacy.

Launch campaign ramped up for disease-modifying drug that targets rare and fatal form of hypertension.

The author discusses how to calm the nerves of workers during periods of uncertainty.